文献速递乳房整形与再造显微修复重建

新辅助化疗方案类型与自体乳房再造并发症的比较

Comparison of Autologous Breast Reconstruction Complications by Type of Neoadjuvant Chemotherapy Regimen.
PubMed 文献 · Plast Reconstr Surg · 2021-01-01

多因素分析显示,含蒽环类方案中紫杉烷先用的顺序与并发症增加相关(OR 3.521,p=0.012),尤其是脂肪坏死(OR 2.481,p=0.040)。化疗剂量、化疗结束至手术间隔及循环免疫细胞数量在并发症组间无显著差异。

要点

  • 含蒽环类新辅助化疗中紫杉烷先用与微血管乳房再造并发症增加相关。
  • 紫杉烷先用方案尤其与脂肪坏死风险升高相关(OR 2.481,p=0.040)。
  • 化疗剂量、手术间隔及循环免疫细胞数量与并发症无显著关联。

核心结论

  • 含蒽环类且紫杉烷先用的新辅助化疗方案与微血管乳房再造并发症增加相关,尤其是脂肪坏死。

研究设计与样本

  • 化疗方案按是否含蒽环类及紫杉烷给药顺序分层,采用卡方、Fisher精确检验和t检验进行单因素分析,多因素二元logistic回归控制协变量。

主要发现

  • 多因素分析中,含蒽环类方案中紫杉烷先用与并发症增加相关(OR 3.521;p=0.012)。
  • 紫杉烷先用与脂肪坏死增加相关(OR 2.481;p=0.040)。
  • 评估紫杉烷先用方案对并发症影响的logistic回归模型AUC为0.760(p<0.0001),脂肪坏死模型AUC为0.635(p<0.05)。
  • 化疗剂量、新辅助化疗结束至手术的天数及循环免疫细胞数量在发生并发症的患者间无显著差异。

临床怎么用

  • 在制定新辅助化疗方案时,需权衡紫杉烷先用方案改善肿瘤结局的获益与乳房再造后并发症(尤其是脂肪坏死)增加的风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Neoadjuvant chemotherapy before mastectomy helps reduce tumor burden and pathologic response in breast cancer. Limited evidence exists regarding how neoadjuvant chemotherapy impacts outcomes following microvascular breast reconstruction. This study examines the effects of neoadjuvant chemotherapy regimens and schedules on microvascular breast reconstruction complication rates and also assesses the effects of neoadjuvant chemotherapy on circulating immune cells related to wound healing. METHODS: Patients who underwent neoadjuvant chemotherapy and microvascular breast reconstruction at Yale New Haven Hospital between 2013 and 2018 were identified. Demographic variables, oncologic history, chemotherapy regimens, and complication profiles were collected. Chemotherapy regimens were stratified by inclusion of anthracycline and order of taxane administration. Chi-square, Fisher's exact, and t tests were used for univariate analysis. Multivariate binary logistic regression was used to control for covariates. RESULTS: One hundred patients met inclusion criteria. On multivariate analysis, the administration of taxane first in an anthracycline-containing chemotherapy sequence was associated with increased complications (OR, 3.521; p = 0.012), particularly fat necrosis (OR, 2.481; p = 0.040). In the logistic regression model evaluating the effect of the taxane-first regimen on complication rates, the area under the curve was estimated to be 0.760 (p < 0.0001), particularly fat necrosis 0.635 (p < 0.05). The dosage of chemotherapy, number of days between neoadjuvant chemotherapy completion and surgery, and number of circulating immune cells did not significantly differ among patients who experienced complications. CONCLUSIONS: Taxane-first, anthracycline-containing neoadjuvant chemotherapy regimens were associated with increased complications, particularly fat necrosis. The increased postreconstruction complication risk must be weighed against the benefits of taxane-first regimens in improving tumor outcome. CLINICAL QUESTION/LEVEL OF EVIDENCE: Therapeutic, III.

来源:Plast Reconstr Surg,查看原文。版权归原作者所有。

引用

  1. Olawoyin OM, Mehta S, Chouairi F, et al. Comparison of Autologous Breast Reconstruction Complications by Type of Neoadjuvant Chemotherapy Regimen. Plast Reconstr Surg. 2021. PMID: 34644277. doi:10.1097/PRS.0000000000008505

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。